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A B S T R A C T
The spectrum of lipid disorders in chronic kidney disease (CKD) is usually characterized by high triglyc-
erides and reduced high dense lipoprotein (HDL), associated with normal or slightly reduced low dense
lipoprotein (LDL)-cholesterol. This dyslipidemia is associated with an increased risk for atherosclerotic
cardiovascular disease. Keys for the cardiovascular risk reduction in these patients are lowering the number
and modifying the composition of the cholesterol-carrying atherogenic lipoprotein particles. Statins have
an important role in primary prevention of cardiovascular events and mortality in non-hemodialyzed
CKD patients. The beneﬁts in terms of progression of renal failure are contradictory. Patient education
regarding dietary regimen should be part of the CKD clinical management.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Lipids are heterogeneous and fundamental biological mol-
ecules which, besides their energetic roles, are involved in cellular
membrane function and synthesis of bile acids, steroid hormones
and vitamin D. Circulating lipids are transported by lipoproteins,
which are hydrosoluble particles constituted by a lipid nonpolar core
of triglycerides and esteriﬁed cholesterol, enveloped by apo-
lipoproteins, phospholipids and others polar lipids. In decreasing
order of density, lipoprotein are divided in high density (HDL), low
density (LDL), intermediate (IDL), very low density (VLDL) lipopro-
teins and chylomicrons [1].
It is well known that high levels of cholesterol-LDL represent an
independent risk factor for atherosclerotic events and all-cause mor-
tality, as shown for the ﬁrst time in 1913 by Nikolay Anichkow [2].
He demonstrated a close direct relationship between aortic ath-
erosclerosis and high cholesterol diet in rabbits. In the last decades,
several larger epidemiological studies conﬁrmed these ﬁnding in
humans, as observed in Framingham Heart Study and Multiple Risk
Factor Intervention Trial, where serum levels of cholesterol-LDLwere
related to coronary artery disease [3,4].
Statins modify profoundly the natural history of atherosclero-
sis and related complications, as they decrease cardiovascular
mortality secondary to reduction of cholesterol-LDL by 20–55% in
a dose-dependent manner after 30 days of therapy [5]. Beyond the
effects on cholesterol levels exerted by the inhibition of hydroxy-
3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, several
pleiotropic effects have been linked to statins acting on inﬂamma-
tion, atheromatous plaques and endothelial dysfunction.
Here, we aim to review the lipid proﬁle in patients with chronic
kidney disease (CKD), patients on hemodialysis, and renal trans-
planted patients. We evaluate the inﬂuence of hyperlipemia on renal
disease progression and cardiovascular outcomes, and the impor-
tance of diet. Finally, we mention future perspectives and potential
new therapies that could improve survival and clinical outcomes
in renal patients.
Chronic kidney disease and cardiovascular risk
The prevalence of CKD varies from 7 to 12.5% [6]. CKD is asso-
ciated with an independent risk factor for cardiovascular disease
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(CVD), which is the main cause of morbidity and mortality in these
patients [7]. Cardiovascular risk occurs early in CKD patients [8]. As
shown in the PREVEND study, albuminuria represents an indepen-
dent risk factor for cardiovascular and all-cause mortality [9],
demonstrating that CKD inﬂuences CVD development and progres-
sion. However, the pathophysiological mechanisms of this correlation
are not fully understood. In addition to arterial hypertension, dia-
betes mellitus or dyslipidemia, many other factors have been related
to cardiovascular risk, such as chronic inﬂammation, uremic toxins,
oxidative stress, reduced nitric oxide levels and an altered calcium-
phosphorus imbalance [10].
CKD patients are usually characterized by high triglycerides and
low HDL levels, normal or slightly reduced cholesterol-LDL [11].
Cholesterol-LDL is not a reliable predictive cardiovascular risk factor
in patients with advanced CKD. Moreover, in ESRD, low cholester-
ol levels have been related to high mortality risk, probably reﬂecting
chronic inﬂammation and malnutrition, leading to a seemingly par-
adoxical reversal of the well-established association of higher lipid
levels with mortality in the general population [12]. The lipid and
apo-lipoprotein proﬁle characterizing pre-dialytic renal failure
remains essentially unchanged during long-term dialysis, with qual-
itative and quantitative alterations.
In particular, disturbances in the density distribution of LDL sub-
fractions have been assessed, showing a predominance of small,
dense LDL particles, more atherogenic than the large ones, sub-
stantially contributing to the pathogenesis of atherosclerotic vascular
disease. These structural modiﬁcations are related to the low tri-
glycerides content within LDL, due to lipoprotein lipase and hepatic
lipase actions [13,14].
High plasma triglyceride levels can also be explained by signif-
icant increases in plasma levels of apolipoprotein C-III, which is a
potent inhibitor of LPL [15]. LPL, which is located in the capillary
endothelium, is responsible for triglyceride and phospholipid hy-
drolysis of VLDL and chylomicrons, leading to their deposition in
arterial vessels [16,17].
High levels of lipoprotein Lp (a) contribute to atherosclerosis
and cardiovascular disease in CKD patients. Lp (a) is an LDL-like
particle in which the speciﬁc apolipoprotein(a) is linked to apoB-
100 by a single disulﬁde bond [18]. In kidney disease, plasma
Lp(a) levels are signiﬁcantly inﬂuenced by the glomerular ﬁltra-
tion rate (GFR), and are increased in the earliest stages of renal
impairment [19].
Furthermore, up-regulated HMG-CoA reductase and increased
acetyl-coenzyme A acetyl-transferase (ACAT)-2 promote the accu-
mulation of esteriﬁed cholesterol and the production of lipoproteins
containing apo-B, namely LDL and VLDL [20].
CKD is associated with a reduced activity of lecithin-cholesterol
acyl-transferase (LCAT), an enzyme linked to HDL and responsible
for the conversion of cholesterol into its esteriﬁed forms, allowing
hepatic removal of cholesterol. LCAT dysfunction causes morpho-
logical changes to HDL, which acquire a spherical rather than disc-
shaped structure, with resulting alteration of their catabolism [21,22].
Furthermore, down-regulation of LP and LPL could be induced by
a mechanistically poorly understood secondary hyperparathyroid-
ism, a common complication observed in CKD leading to worsening
dyslipidemia [23]. Indeed, hypotriglyceridemia was reported after
parathyroidectomy [24] and high levels of phosphorus are notori-
ously associated with an increased risk of cardiovascular mortality,
independent of calcium or parathyroid hormone levels [25].
Statins in patients with renal disease: role in cardiovascular
outcomes
Whereas several studies have clearly demonstrated beneﬁcial
effects of statins on cardiovascular morbidity and mortality, con-
trasting data have been obtained when the CKD population has been
evaluated [26]. Nevertheless, recent studies highlighted positive
results also in CKD patients, independent of cholesterol levels.
(Table 1) In particular, the Heart Protection Study [27] and the Anglo-
Scandinavian Cardiac Outcomes (ASCOT) trial [31] demonstrated a
reduction of cardiovascular morbidity and mortality in CKD pa-
tients treated with simvastatin. The Pravastatin Pooling Project data
demonstrated that cardiovascular outcomes, including myocar-
dial infarction, coronary revascularization and cardiac death, were
reduced by this statin in CKD patients [29]. The Treating to New
Targets (TNT) study compared the effects of two dosages of
atorvastatin on cardiovascular events, revealing better outcomeswith
the higher statin dosage in patients with renal failure [33]. Similar
conclusions were obtained by the Aggressive Lipid-Lowering Ini-
tiation Abates New Cardiac Events (ALLIANCE) study, in which
atorvastatin reduced the relative risk of cardiovascular events by
28% in CKD patients and by 11% in patients without evidence of
renal disease [36]. Positive results were also reported administer-
ing rosuvastatin. In the Justiﬁcation for the Use of statins in
Table 1
Trials evaluating the reduction of cholesterol-LDL and cardiovascular risk in CKD populations
Trials N° Patients, disease Statin dosage Follow-up (years) LDL reduction % CV event reduction % P value
HPS (2002) [27] 1329 CKD Simvastatin
40 mg
5 29% 28% <0.001
SHARP (2011) [28] 9270 CKD and hemodialysis Simvastatin
20 mg + Ezetimibe
10 mg
4.9 55% 17% 0.0021
PPP (2004) [29] 4491 CKD Pravastatin
40 mg
5 31% 23% <0.02
ALERT (2005) [30] 2102 Renal transplant Fluvastatin
40 mg
5.1 32% 29% <0.01
ASCOT (2003) [31] 6517 Arterial hypertension
CKD
Atorvastatin
10 mg
3.3 29% 40% 0.0025
4D (2005) [32] 1255 Hemodialysis Atorvastatin
20 mg
4 42% – 0.35
TNT (2008) [33] 1602 CKD Atorvastatin
80 mg
5 36% 32% 0.0003
AURORA (2009) [34] 2776 Hemodialysis Rosuvastatin
10 mg
3.8 43% – 0.59
JUPITER (2010) [35] 3267 CKD Rosuvastatin
20 mg
4 40% 45% 0.002
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Prevention – an Intervention Trial Evaluating Rosuvastatin (JUPITER)
trial, CKD patients receiving rosuvastatin had a reduction in myo-
cardial infarction, ischemic stroke and cardiovascular mortality by
45% compared to placebo [35].
Convincing data were also obtained in renal transplanted pa-
tients. In particular, the ALERT study (Assessment of Lescol in Renal
Transplant) evaluated the effects of ﬂuvastatin, revealing better car-
diovascular outcomes than those recorded in the placebo group.
However, renal graft survival and all-cause mortality were not in-
ﬂuenced by statin treatment in this study [30,37]. Overall these data
demonstrate that statins exert positive effects in patients with CKD.
However, these beneﬁcial effects have not been demonstrated in
ESRD patients. Several trials have been conducted in patients un-
dergoing HD. The 4D Study (Die Deutsche Diabetes Dialyse Studie)
demonstrated that there were no differences between the treated
and untreated groups in the primary composite endpoint of cardiac
death, stroke, or nonfatal myocardial infarction, whereas in the
atorvastatin group, there was a two-fold increase in fatal strokes
[32]. Similar conclusions emerged from the AURORA trial, a ran-
domized placebo-controlled trial the enrolled over 2000 HD patients
treated with rosuvastatin [34]. Different explanations could be pro-
posed for these negative results. First, many cardiovascular events
in dialysis patients were due to arrhythmia or non-ischemic car-
diomyopathy, whichmight not be related to atherosclerosis. Second,
the atherosclerosis was so advanced that these patients were un-
likely to beneﬁt from drug therapy [38].
The Study of Heart and Renal Protection (SHARP) was a pro-
spective trial using statins in more than 3000 HD patients,
randomized to simvastatin 20mg/day or simvastatin 20mg/day plus
ezetimibe or placebo. During a follow-up period of 4.9 years, the
greatest reduction of cholesterol-LDL and cardiovascular events was
obtained in patients treatedwith simvastatin plus ezetimibe, without
achieving statistical signiﬁcance and without differences on mor-
tality rate [28].
Lipids and statins: role in CKD
Several studies have demonstrated an association between ab-
normal lipidmetabolism and progression of renal disease, but results
are controversial. Whereas in vitro and animal studies suggest an
important role of lipid alterations in initiation and progression of
CKD, human studies did not provide uniform data.
Experimental studies
Animal studies have demonstrated that lipid alterations induce
glomerular and tubular damage, with positive effects exerted by
statin therapy [39]. The mechanisms are not fully understood, but
the main hypothesized explanation is linked to the inhibition of
mevalonate, a well known stimulant of cellular replication and glo-
merular proliferation.
Kasiske et al. evaluated the effects of lovastatin in obese and al-
buminuric rats with focal glomerulosclerosis [40]. They found a
reduction of urine albumin excretion and an improvement of glo-
merular sclerosis in the treated group compared to placebo. Potential
beneﬁcial effects by statin treatment in glomerular disease were
evaluated in a rat model of mesangial proliferative glomerulone-
phritis induced by anti-thymocyte antibodies. A suppression of 70%
of glomerular cell proliferation was shown, together with a de-
creased glomerular alpha-smoothmuscle actin expression, a marker
formesangial cell activation. Furthermore, an inhibition of monocyte/
macrophage recruitment into glomeruli by simvastatin was also
demonstrated [41].
Human studies
Several studies have been performed to assess the role of lipids
in the development and progression of CKD. Mänttäri and col-
leagues reported an independent association between high LDL levels
and decline of renal function in 2.702 dyslipidemic patients [42].
They also reported an elevated LDL/HDL ratio (>4.4) which was as-
sociated with a worse loss of renal function. However, the relatively
short follow-up period of 5 years and the exclusive use of creati-
nine as marker of renal function are major limitations of this study.
Similar conclusions were achieved byMuntner et al., evaluating over
2000 subjects [43]. In particular, high triglyceride and lowHDL levels
were independent risk factors for renal dysfunction. Conversely,
cholesterol-LDL values were not predictive for increased risk of
kidney injury, but the short follow-up period of 2.9 years could be
an important limitation.
In a 14-year follow-up period, Schaeffner et al. demonstrated a
signiﬁcant association between abnormal cholesterol parameters,
such as low HDL levels, and development of renal dysfunction [44].
Furthermore, in a prospective controlled open-label trial the
effects of one-year treatment with atorvastatin on proteinuria and
progression of kidney disease were evaluated in 56 CKD patients
[45]. After one year, urine protein excretion and rate of progres-
sion of kidney disease decreased in patients treatedwith atorvastatin
in associationwith angiotensin-converting enzyme inhibitors (ACEIs)
or angiotensin AT1 receptor antagonists (ARBs).
However the SHARP trial, which evaluated the effects of
simvastatin plus ezetimibe on cardiovascular outcomes in CKD pa-
tients, failed to conﬁrm a beneﬁt on renal disease progression [46].
Recently, the CRIC study failed to demonstrate the predictive role
of measured plasma lipids and lipoproteins on the progression of
kidney disease in over 2000 patients with CKD [47]. Moreover, nu-
merousmeta-analyses led to similar results. In particular, Sanguankeo
et al. concluded that only high-intensity therapy with statins can
improve GFR decline, whereas moderate- and low-intensity statins
did not achieve the same positive results. Furthermore, this anal-
ysis demonstrated that statin therapy did not reduce proteinuria
in CKD patients [48].
Another recent meta-analysis, including 57 studies with a total
of 143,888 participants, revealed that statins do not reduce the risk
of kidney failure, but improved proteinuria [49]. Finally, recent studies
showed that the pleiotropic actions of statins may induce beneﬁ-
cial effects in the formation and expansion of kidney cysts in
autosomal dominant polycystic kidney disease (ADPKD) [50,51].
In conclusion, whereas hypolipidemic drugs should be recom-
mended to prevent and reduce atherosclerotic disease incidence in
CKD patients, convincing evidence does not exist to consider their
use for slowing the progression of renal disease. Moreover, most
of these studies are post-hoc analyses that were not speciﬁcally de-
signed to evaluate the eﬃcacy of statin therapy in preserving kidney
function.
Nutritional aspects of lipid disorders in CKD
CKD management often includes nutritional recommendations
to reduce protein intake and to regulate electrolyte disorders.
However, little attention is dedicated to lipid consumption, prob-
ably due to contrasting data emerging from trials about their role
in CKD progression. Nevertheless, considering that dyslipidemia rep-
resents an independent risk factor for cardiovascular disease, dietary
fat intake should bemonitored from a quantitative and quality points
of view [52].
The long-term effect of low-fat, Mediterranean, or low-
carbohydrate diets has been examined in CKD patients with or
without diabetes mellitus, evaluating urinary albumin excretion and
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GFR. Signiﬁcant improvements in renal function were achieved in
all dietary regimens, independently of confounding factors, such as
use of ACEIs or weight loss. However, a decrease in fasting insulin
and systolic blood pressure remained associated with GFR after mul-
tivariate analysis, contributing to the observed improvements [53].
Furthermore, the association between CKD and macronutrient
intake, including total, animal, and plant proteins, carbohydrate,
simple sugar, fructose, total fat, saturated fatty acids, poly- and
monounsaturated-fatty acids (PUFA and MUFA), and n-3 and n-6
fatty acids, was assessed.
After adjustment for serum triglycerides and cholesterol, body
mass index, and hypertension, the risk of CKD decreased in the
highest quartile compared to the lowest quartile of plant proteins,
PUFA and n-6 fatty acids, while animal proteins may be a risk factor
for CKD in adults [54].
In patients with renal transplantation, low-lipid and low-
caloric diet allowed the avoidance of hyperﬁltration, reduction of
hyperlipidemia and obesity, lowering the prevalence of metabolic
syndrome [55]. These data demonstrated the importance of dietary
prescription, including quantity and quality of fats in CKD patients.
New therapeutical approach
Whereas high cholesterol-LDL levels are closely related to in-
creased cardiovascular morbidity and mortality risk in general
population, their utility as a marker in CKD patients remains unclear.
Indeed, in patients with impaired GFR values the association between
higher LDL-C and risk of myocardial infarction was weak [56]. More-
over, hemodialysis patients are characterized by low LDL values
associated with high cardiovascular risk, reﬂecting the complex
puzzle constituted by several, independent and prognostic factors,
such as chronic inﬂammation, malnutrition or vascular calciﬁca-
tion [57,58].
Initially, in the general population, the purpose of hypolipidemic
treatments was to achieve a correct cholesterol-LDL level and reduce
cardiovascular risk (treat to target method) [59]. This was ob-
tained with the highest tolerated dose to obtain the most beneﬁts,
despite an increased risk of side effects. In 2013 new guideline
changed this therapeutical approach [60]. This was especially true
in CKD patients, with several comorbidities, and for these reasons
subjected to multiple therapies. In particular, lower dosage of statins
is suggested in patients with GFR lower than 60 ml/min/1.73 m2 or
in ESRD, without the need to achieve a speciﬁc target of cholesterol-
LDL. This strategy, deﬁned as “ﬁre and forget”, is based on exclusive
initial evaluation of lipid proﬁle, to exclude severe hypercholester-
olemia, hypertriglyceridemia or secondary causes of dyslipidemia,
since there are no evidences of beneﬁts for frequent lipid measure-
ments [61].
According to these considerations, Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines recommended an initial
monotherapy with statins or statins plus ezetimibe in patients older
than 50 years and GFR lower than <60 ml/min/1.73 m2. In patients
younger than 50 years of age, hypolipidemic therapy is recom-
mended for those with high cardiovascular risk (diabetes mellitus,
existence of cardiovascular disease or 10-year risks >10%).
In hemodialysis patients statins should not be initiated de novo,
given the lack of beneﬁcial effects on cardiovascular risk, whereas it
should be continued for those already receiving treatment. In renal
transplant patients, statins are suggested, due to their high coronary
heart disease risk. Hypertriglyceridemia should be initially corrected
with lifestyle modiﬁcation, adding ﬁbrates only for triglyceride
levels >1000mg/dl due to the high acute pancreatitis risk [62].
Future perspectives
Although statins improve cardiovascular morbidity and mortal-
ity, there is still a percentage of patients not at target for LDL and,
therefore, at high risk for cardiovascular disease. In the last years,
several hypolipidemic drugs, with different mechanisms, have been
studied (Table 2).
Antisense oligonucleotides (ASO)
This group of drugs is characterized by nucleotide sequences that
are complementary to RNA sense. These single-stranded DNA or RNA
molecules bind speciﬁc regions of mRNA, inhibiting the synthesis
of the corresponding protein, as obtained for apolipoprotein B100.
The consequent impaired synthesis of apoB-100 induces a de-
crease in serum levels of LDL and Lp(a), since apoB-100 is the
essential apolipoprotein of these atherogenic lipoproteins [70].
Mipomersen, considered the precursor of the ASO hypolipidemic
drugs, has been approved by the Food and Drug Administration for
patients with homozygous familial hypercholesterolemia in asso-
ciation with classic hypolipidemic drugs and speciﬁc lifestyle and
dietary prescriptions. When compared to placebo, mipomersen
showed better results in terms of LDL reduction, despite a greater
number of side effects, such as skin reactions, ﬂu-like symptoms
and reversible hepatic enzyme increment [63]. These adverse re-
actions led the European Medicines Agency (EMA) to deny approval
for mipomersen.
Microsomal triglyceride transfer protein (MTP) inhibitors
MTP is an intracellular protein responsible for the binding and
movement of lipids through the cellular membrane and plays a
pivotal role in the synthesis of apo-B, leading to lower levels of cho-
Table 2
New hypolipidemic drugs
Molecule Pharmacological
class
Patients Dosage Follow-up
(years)
LDL
reduction
Trial phase
Mipomersen [63] (not
approved by EMA)
ASO 158 Patients with hypercholesterolemia and high
cardiovascular risk
200 mg/week 2 37% 3
Lomitapide [64] MTP inhibitor 29 Patients with homozygous familial hypercholesterolemia 60 mg/day 4.3 50% 3
Alirocumab [65] PCSK9 inhibitor 2341 Patients with high cardiovascular risk and LDL > 70 mg/dl 150 mg/2 weeks 2 62% 3
Evolocumab [66] PCSK9 inhibitor 4465 Patients with high cardiovascular risk 140 mg/2 weeks 0.93 62% 3
Bococizumab [67] PCSK9 inhibitor 354 Patients with hypercholesterolemia 50, 100, and
150 mg/2 weeks
2 33.4–53.4% 2
Anacetrapib [68] CEPT inhibitor 1623 Patients with high cardiovascular risk 100 mg/day 2–6 39.8% 3
On going
Evacetrapib [69] CEPT inhibitor 398 Patients with hypercholesterolemia 30, 100, and
500 mg/day
1 13.6–35.9% 2
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lesterol and triglycerides. Clinical applications of MTP inhibitors have
been focused particularly in patients with homozygous familial
hypercholesterolemia.
Lomitapide, an orally administered MTP inhibitor, was tested in
29 patients affected by homozygous familial hypercholesterol-
emia, at escalating daily doses of 5 to 60mg, and demonstrated safety
and tolerability with a reduction of serum LDL cholesterol by 50%
from baseline. Gastrointestinal symptoms were the most common
adverse events, whereas four patients had reversible increase in
amino-transaminase levels that did not lead to drug discontinua-
tion [64]. Moreover, in the following 5 years no additional side effects
or metabolic complications were observed [71]. Based on these
promising data, FDA and EMA approved this drug for treating pa-
tients with homozygous familial hypercholesterolemia, in addition
to low-fat diet and other hypolipidemic drugs.
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
PCSK9, which belongs to the family of proprotein convertases,
binds LDL receptors (LDLr) thus preventing the removal of LDL par-
ticles from the blood. Inhibiting PCSK9 results in improved LDLr
recycling, increased LDLr availability on hepatocyte cell surfaces, and
reduced blood LDL-C levels.
In the last years, several molecules have been tested to block
PCSK9, but only speciﬁc monoclonal antibodies were approved for
clinical use. In particular, alirocumab, evolocumab and bococizumab,
administered subcutaneously every two to four weeks, lead to a re-
duction of cholesterol-LDL by 50%.
Alirocumab demonstrated a signiﬁcant reduction of LDL cho-
lesterol levels in a recent randomized trial, involving more than two
thousands patients at high risk for cardiovascular events. The post-
hoc analysis showed also a reduction in the rate of cardiovascular
events.
Injection site reactions, myalgia, neuro-cognitive disorders and
visual dysfunctions were the major side effects recorded [65].
Similarly, the Osler-1 and Osler-2 trials revealed positive effects
of evolocumab, in addition to other hypolipidemic drugs, on
cholesterol-LDL levels. Exploratory analysis demonstrated beneﬁ-
cial effect on cardiovascular events. Neuro-cognitive alterations
represented the most common side effects [66].
Data from a phase 3 trial evaluating bococizumab will be avail-
able in 2018. Nevertheless, phase 2 studies showed a signiﬁcant
reduction of LDL cholesterol compared to placebo, without differ-
ences in side effects between the two groups [67].
Cholesteryl ester transfer protein (CETP) inhibitors
Cholesteryl ester transfer protein (CETP) promotes the transfer
of esteriﬁed cholesterol and triglycerides from HDL to lipopro-
teins expressing apo B, such as VLDL and LDL.
The inhibition of this protein induces increased levels of HDL and
decreased levels of LDL.
The phase 3 trial with torcetrapib, the ﬁrst CEPT inhibitor, was
interrupted due to the high mortality rate in the treated group [72].
The same complication was observed with Dalcetrapib, which,
despite positive effects on HDL levels, did not show a reduction of
cardiovascular events [73].
A recent trial showed that evacetrapib, a new CEPT inhibitor, as
monotherapy or in association with statin, reduced the concentra-
tions of atherogenic apoB-containing lipoproteins, including Lp(a),
LDL-P, and sLDL [69]. Another molecule, anacetrapib, is being evalu-
ated in a phase 3 trial, that is expected to give deﬁnitive answers
on safety and effectiveness of this class of hypolipidemic drugs [68].
To date, no data are available about the effects of these novel
drugs on renal outcomes, such as the progression of chronic renal
failure. Homozygous familial hypercholesterolemia is the main in-
dication for these novel agents, although patients at high
cardiovascular riskmay represent, in our opinion, an emerging target
population.
Ongoing trials are evaluating the effects of these drugs on car-
diovascular disease. In particular, a multi-center long-term open-
label non-comparative study will evaluate carotid and aortic
atherosclerosis, in patients treated with lomitapide [74]. More-
over, a randomized, double-blind, placebo-controlled trial will
evaluate the effect of Alirocumab on the occurrence of cardiovas-
cular events in patients with recent episodes of acute coronary
syndrome [75]. However, whether these new therapeutic options
will be effective and safe, alone or in combination with statins, and
lead to beneﬁcial effects on cardiovascular disease morbidity and
mortality and renal disease progression in CKD will require further
evaluation.
Conclusion
CKD patients are characterized by high cardiovascular risk, which
begins in the early stages of the disease. Comorbidities, such as ar-
terial hypertension, diabetes mellitus and dyslipidemia, contribute
to this risk.
Statins exert positive effects in CKD and in renal transplanted
patients, whereas no advantages have been revealed in ESRD, in
terms of survival or cardiovascular morbidities.
New hypolipidemic therapies lead to an additional lowering of
cholesterol levels, but further studies are necessary to evaluate their
potential application to CKD patients in order to improve clinical
outcomes.
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